Biocon tanks 4% as USFDA defers decision on Avastin biosimilar application

Biocon's arm Biocon Biologics and Mylan, a subsidiary of Viatris Inc, have been informed by the USFDA of a deferred action on the BLA for MYL-1402O, a proposed biosimilar to Avastin (bevacizumab).

from Markets-Economic Times https://ift.tt/3mXwwRH